ArticleProceedings of the National Academy of Sciences of the United States of America2023
Innate immune cell activation causes lung fibrosis in a humanized model of long COVID.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Extracellular Vesicle-Delivered tRF-His-GTG-1 Reprograms Neutrophil Lipophagy and Triggers Inflammation in COVID-19.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Dysregulated NK-cell gene expression defines the enduring symptoms of long COVID-19.Frontiers in immunology · 2026Article
- Engineering an immune-integrated lung-on-a-chip to reveal TOX-RAGE axis-driven fibrosis and RAGE blockade as a therapeutic strategy.Nano convergence · 2025Article
- Review
- The potential of efferocytosis for the treatment of bronchial asthma: A review of current trends, mechanisms and prospects.Biochemistry and biophysics reports · 2025Review
- Pulmonary and Immune Dysfunction in Pediatric Long COVID: A Case Study Evaluating the Utility of ChatGPT-4 for Analyzing Scientific Articles.Journal of clinical medicine · 2025Review
- Breathless Aftermath: Post-COVID-19 Pulmonary Fibrosis.Viruses · 2025Review
- Beyond cancer: The potential application of CD47-based therapy in non-cancer diseases.Acta pharmaceutica Sinica. B · 2025Review
- IL-33 and IL-3 synergistically induce CD25 expression on human basophils without functional IL-2 signaling: a potential marker of severe COVID-19.Frontiers in immunology · 2025Article
- Retrospective cohort analysis on predicting pulmonary fibrosis in elderly SARS-CoV-2-infected patients.Frontiers in cellular and infection microbiology · 2025Article
- Animal models of Long Covid: A hit-and-run disease.Science translational medicine · 2024Review
- Translating insights into therapies for Long Covid.Science translational medicine · 2024Review
- Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report.Annals of the American Thoracic Society · 2024Review
- Challenges and opportunities in long COVID research.Immunity · 2024Article
- Clinical coding of long COVID in primary care 2020-2023 in a cohort of 19 million adults: an OpenSAFELY analysis.EClinicalMedicine · 2024Article
- The role of the cytoskeleton in fibrotic diseases.Frontiers in cell and developmental biology · 2024Review
- Tracking inflammation resolution signatures in lungs after SARS-CoV-2 omicron BA.1 infection of K18-hACE2 mice.PloS one · 2024Article
- Dynamic shifts in lung cytokine patterns in post-COVID-19 interstitial lung disease patients: a pilot study.Therapeutic advances in chronic disease · 2024Article
- MAFB shapes human monocyte-derived macrophage response to SARS-CoV-2 and controls severe COVID-19 biomarker expression.JCI insight · 2023Article
- Proximal immune-epithelial progenitor interactions drive chronic tissue sequelae post COVID-19.Research square · 2023Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
COVID-19 remains a global pandemic of an unprecedented magnitude with millions of people now developing "COVID lung fibrosis." Single-cell transcriptomics of lungs of patients with long COVID revealed a unique immune signature demonstrating the upregulation of key proinflammatory and innate immune effector genes CD47, IL-6, and JUN. We modeled the transition to lung fibrosis after COVID and profiled the immune response with single-cell mass cytometry in JUN mice. These studies revealed that COVID mediated chronic immune activation reminiscent to long COVID in humans. It was characterized by increased CD47, IL-6, and phospho-JUN (pJUN) expression which correlated with disease severity and pathogenic fibroblast populations. When we subsequently treated a humanized COVID lung fibrosis model by combined blockade of inflammation and fibrosis, we not only ameliorated fibrosis but also restored innate immune equilibrium indicating possible implications for clinical management of COVID lung fibrosis in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.